.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Johnson and Johnson
Accenture
Merck
Colorcon
Chubb
Mallinckrodt
Cipla
Farmers Insurance

Generated: December 12, 2017

DrugPatentWatch Database Preview

Par Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?

PAR PHARM has two hundred and twelve approved drugs.

There is one US patent protecting PAR PHARM drugs on PAR PHARM drugs in the past three years. There are fourteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and seventeen supplementary protection certificates in twelve countries.

Summary for Par Pharm

International Patents:9
US Patents:1
Tradenames:124
Ingredients:121
NDAs:212
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Par Pharm IncTIZANIDINE HYDROCHLORIDEtizanidine hydrochlorideTABLET;ORAL207170-001Jan 26, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par Pharm IncBALSALAZIDE DISODIUMbalsalazide disodiumTABLET;ORAL206336-001Sep 8, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-006Sep 17, 1986DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmOMEPRAZOLE AND SODIUM BICARBONATEomeprazole; sodium bicarbonateCAPSULE;ORAL078966-001May 25, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par Pharm IncZOLPIDEM TARTRATEzolpidem tartrateTABLET;SUBLINGUAL204229-001Sep 11, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmQUETIAPINE FUMARATEquetiapine fumarateTABLET, EXTENDED RELEASE;ORAL090482-005May 9, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmTRANYLCYPROMINE SULFATEtranylcypromine sulfateTABLET;ORAL040640-001Jun 29, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmMINOCYCLINE HYDROCHLORIDEminocycline hydrochlorideTABLET;ORAL065131-001Apr 16, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par Pharm IncROSUVASTATIN CALCIUMrosuvastatin calciumTABLET;ORAL079168-002Jul 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Par PharmMETAPROTERENOL SULFATEmetaproterenol sulfateTABLET;ORAL072024-001Jun 28, 1988RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Par Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-004Jun 13, 1995► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-004Jun 13, 1995► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-007Jun 13, 1995► Subscribe► Subscribe
Par PharmNASCOBALcyanocobalaminGEL, METERED;NASAL019722-001Nov 5, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par PharmCAPOTENcaptoprilTABLET;ORAL018343-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PAR PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalaminNasal Spray500 mcg/sprayNASCOBAL4/28/2017
zafirlukastTablets10 mg and 20 mgACCOLATE2/29/2008

International Patent Family for Par Pharm Drugs

Country Document Number Estimated Expiration
China101163679► Subscribe
South Korea20080000660► Subscribe
Australia2006240490► Subscribe
Japan5378788► Subscribe
Mexico2007013118► Subscribe
Japan2008538560► Subscribe
Canada2605413► Subscribe
European Patent Office1948613► Subscribe
World Intellectual Property Organization (WIPO)2006115626► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Par Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
2012017Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
80022Netherlands► SubscribePRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
C0048France► SubscribePRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
/1997Austria► SubscribePRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Novartis
Accenture
Julphar
Teva
Covington
McKesson
Fuji
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot